Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial antigen of prostate 1 (STEAP1).

The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.

Orion Corp. and Invenra Inc. have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform.

Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.

Lifearc has announced a collaboration with Neuropeutics Inc. to develop a new small molecule for the treatment of motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS). Neuropeutics and Lifearc intend to develop a lead candidate therapeutic to prevent and reverse TDP-43 protein aggregation in MND/ALS.

Tevogen Bio Holdings Inc. has expanded its relationship with Microsoft Corp. to broaden their AI-focused collaboration and build its Predictcell technology for predictive precision T-cell targeting.

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

Immuron Ltd. has signed a new research collaboration agreement with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens. This work will utilize the Immuron technology platform, and the experience of the Biomedicine Discovery Institute research team.

Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to combine nucleic acid drug delivery technology developed at Stanford with the genome editing technology of Emendobio Inc., a subsidiary of Anges.